ASX Share rice
Fri 14 Aug 2020 - 05:22:pm (Sydney)

BD1 Share Price

BARD1 LIFE SCIENCES LIMITEDBD1Health Care Equipment & Services

BD1 Company Information

Name:

BARD1 Life Sciences Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

GIC Industry:

Health Care Providers & Services

GIC Sub Industry:

Health Care Services

Address:

Unit 202 39 Mends Street South Perth Australia 6151

Phone:

61 8 9381 9550

Chief Exec. Officer:

Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.

Founder, Exec. Director & Chief Scientific Officer:

Dr. Irmgard Irminger-Finger B.Sc., M.Sc., PD, Ph.D.

Managing Director:

Mr. Peter Lynton Gunzburg B Comm, ASIA

CFO & Company Sec.:

Mr. Tony Di Pietro

Chief Operating Officer:

Mr. Carl S. Stubbings

Company Overview:

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test for the early detection of lung cancer in high-risk asymptomatic individuals; and BARD1 ovarian cancer test to detect ovarian cancer in high-risk women with a family history of breast/ovarian cancer or carrying BRCA1/2 mutations. The company has a collaboration with the Institute for Respiratory Health to evaluate a potential BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models. BARD1 Life Sciences Limited is based in South Perth, Australia.

BD1 Share Price Information

Shares Issued:

2.39B

Market Capitalisation:

$74.23M

Revenue (TTM):

$598.10K

Earnings per Share:

$-0.001

Operating Margin (TTM):

$-4.04

Return On Assets (TTM):

$-0.24

Return On Equity (TTM):

$-0.42

Quarterly Revenue Growth (YOY):

0.984

Gross Profit(TTM):

$-142,775

Diluted Earnings Per Share (TTM):

$-0.002

BD1 CashFlow Statement

CashFlow Date:

2019-06-30

Change To Liabilities:

$181.48K

Net Income:

$-1,717,273

Total Cash From Operating Activities:

$-1,570,719

Change To Account Receivables:

$-57,813

Sale Purchase Of Stock:

$-604,024

Capital Expenditures:

$0

BD1 Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-1,717,273

Net Income:

$-1,717,273

Gross Profit:

$-142,775

Operating Income:

$-2,302,240

Total Revenue:

$570.99K

Total Operating Expenses:

$2.30M

Cost Of Revenue:

$713.76K

BD1 Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$491.86K

Total Stockholder Equity:

$7.13M

Other Current Liabilities:

$35.49K

Total Assets:

$7.63M

Common Stock:

$16.98M

Retained Earnings:

$-9,574,626

Other Liabilities:

$28.66K

Cash:

$7.56M

Total Current Liabilities:

$463.20K

Net Tangible Assets:

$7.13M

Total Current Assets:

$7.63M

Net Receivables:

$61.28K

Short-Term Investments:

$0

Accounts Payable:

$427.71K

Non Currrent Assets (Other):

$0

Short-Term Investments:

$0

Non Current Liabilities Total:

$28.66K

BD1 Share Price History

BD1 News

16 May, 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
17 Mar, 2020
The last three months have been tough on BARD1 Life Sciences Limited (ASX:BD1) shareholders, who have seen the share...
17 Jan, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
18 Nov, 2019
Every investor in BARD1 Life Sciences Limited (ASX:BD1) should be aware of the most powerful shareholder groups...